Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARISOPRODOL COMPOUND vs DANTRIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.
Dantrolene inhibits calcium release from the sarcoplasmic reticulum by binding to the ryanodine receptor (Ry R1), thereby reducing intracellular calcium concentration and decreasing muscle contraction.
Relief of discomfort associated with acute, painful musculoskeletal conditions,As an adjunct to rest, physical therapy, and other measures
FDA approved for the treatment of spasticity in upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, multiple sclerosis),Malignant hyperthermia (acute treatment and prevention),Neuroleptic malignant syndrome (off-label),Ecstasy (MDMA) intoxication (off-label)
1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.
Initially 25 mg orally once daily for 7 days, then 25 mg three times daily for 7 days, then 50 mg three times daily for 7 days, then 100 mg three times daily; maximum 400 mg/day in divided doses. For malignant hyperthermia crisis: IV bolus 1 mg/kg, repeated as needed up to 10 mg/kg cumulative dose.
Carisoprodol has a terminal elimination half-life of approximately 1.5–2 hours; its active metabolite meprobamate has a half-life of 9–12 hours, which may lead to prolonged effects with chronic use.
Terminal elimination half-life: 8.7-14.4 hours in adults; longer with hepatic dysfunction.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite). Aspirin is hydrolyzed by esterases in the liver and plasma to salicylic acid, which is further conjugated. Codeine is metabolized by CYP2D6 to morphine (active) and by CYP3A4 to norcodeine.
Metabolized in the liver via microsomal enzymes (CYP3A4 and others) to 5-hydroxydantrolene (active metabolite) and other metabolites. Undergoes enterohepatic recirculation.
Carisoprodol is primarily metabolized in the liver, with about 50% excreted renally as unchanged drug and metabolites; the major metabolite meprobamate is also renally excreted. Fecal excretion is negligible (<2%).
Renal: ~65% as unchanged drug; biliary/fecal: ~15% as metabolites; remainder metabolized and eliminated via urine.
Carisoprodol is approximately 60% bound to plasma proteins, mainly albumin.
~90% bound to albumin.
Volume of distribution is approximately 0.6–0.8 L/kg, indicating distribution into total body water.
Vd: 0.8-1.2 L/kg; suggests extensive tissue distribution.
Oral bioavailability is nearly complete (close to 100%) due to rapid and extensive absorption.
Oral: ~70% (first-pass metabolism reduces from ~90% absorbed).
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild-moderate impairment; use caution.
No specific guidelines; use with caution in renal impairment due to potential accumulation. Monitor renal function and reduce dose if toxicity occurs.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment, reduce dose or increase interval; specific guidelines not established.
Contraindicated in active hepatic disease (elevated AST/ALT, hepatitis, cirrhosis). For Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 75%; Child-Pugh C: avoid use.
Not recommended for pediatric patients due to aspirin content and risk of Reye syndrome.
Spasticity: 0.5 mg/kg/dose twice daily, titrate up to 0.5-2 mg/kg/dose three times daily; maximum 100 mg four times daily for children >5 years. Malignant hyperthermia: IV 1 mg/kg, repeated as needed.
Initiate at lowest effective dose; monitor for CNS depression, falls, and aspirin-related bleeding. Avoid in patients ≥65 years due to risks of dizziness, sedation, and GI bleeding.
Start at lower end of dosing range (25 mg daily), titrate slowly. Increased risk of sedation, muscle weakness, and hepatic toxicity. Monitor liver function frequently.
None
Hepatotoxicity: Dantrolene can cause fatal hepatitis, especially with long-term use (≥60 days) and at doses >300 mg/day. Liver function must be monitored before and during therapy. Risk is increased in females, patients >35 years, and those on other hepatotoxic medications.
Risk of dependence, abuse, and withdrawal with carisoprodol and codeine,CYP2D6 ultrarapid metabolizers may have morphine toxicity from codeine,Reye's syndrome risk in children with viral illness (aspirin),GI bleeding risk with aspirin,Respiratory depression with codeine,Sedation and impaired motor function,Hepatic impairment,Renal impairment
Monitor liver function tests (LFTs) before and during therapy; discontinue if hepatic injury suspected.,May cause muscle weakness, impair ability to drive or operate machinery.,Caution in patients with compromised respiratory function or impaired cardiac function due to negative inotropic effects.,Photosensitivity reactions possible.,Risk of pleural effusion and pericarditis with long-term use.,Use with caution in renal impairment (no dosage adjustment needed, but monitor).
Hypersensitivity to carisoprodol, meprobamate, aspirin, codeine, or any component,Porphyria,Acute intermittent porphyria,Children with viral illness (aspirin) due to Reye's syndrome risk,Breastfeeding (codeine),Severe renal or hepatic impairment,GI bleeding or peptic ulcer disease (aspirin),Concurrent use of MAOIs or within 14 days,Respiratory depression (codeine)
Active hepatic disease (e.g., hepatitis, cirrhosis),Patients in whom muscle weakness is undesirable (e.g., myasthenia gravis, amyotrophic lateral sclerosis),Hypersensitivity to dantrolene or any component of the formulation,Breastfeeding (discontinue or do not breastfeed; potential for serious adverse reactions in infants)
Avoid alcohol and grapefruit juice. Alcohol increases CNS depression and risk of hepatotoxicity. Grapefruit juice may inhibit metabolism, leading to increased levels and toxicity.
No specific food interactions are established. Avoid alcohol due to additive CNS depression.
Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fetal harm if used during the first trimester due to possible neural tube defects based on limited reports. In the second and third trimesters, maternal use may cause neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) and respiratory depression if used near term. Carisoprodol is not recommended during pregnancy unless benefit outweighs risk.
Dantrolene (Dantrium) is classified as FDA Pregnancy Category C. Animal studies have shown an increased incidence of fetal resorptions and delayed ossification at doses ≥ 30 mg/kg/day in rats and 45 mg/kg/day in rabbits. There are no adequate and well-controlled studies in pregnant women. Potential risks include skeletal anomalies and embryotoxicity. Use only if potential benefit justifies potential risk to fetus.
Carisoprodol is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2-4 based on small studies. An infant would receive a weight-adjusted dose of about 4-8% of the maternal dose, which may cause sedation, drowsiness, or irritability in the neonate. Breastfeeding is not recommended during carisoprodol use, especially in premature infants or those with hepatic impairment. If used, monitor infant for signs of CNS depression.
Dantrolene is excreted in breast milk at low levels; M/P ratio is approximately 0.5 based on limited data. Theoretical risk of muscle weakness and CNS effects in nursing infants. Caution advised; monitor infant for sedation, hypotonia, or feeding difficulties. Consider alternative therapy if possible.
No specific dosing adjustments for carisoprodol are established in pregnancy. However, due to increased plasma volume and altered hepatic metabolism in pregnancy, the drug's half-life may be reduced. Clinical monitoring for efficacy and maternal side effects (e.g., drowsiness, dizziness) is recommended. Use the lowest effective dose for the shortest duration. Consider avoidance of the compound formulation with aspirin or other NSAIDs, which have additional risks.
No specific pharmacokinetic studies in pregnancy; use lowest effective dose. Consider increased clearance due to pregnancy-induced changes; monitor clinical response and adjust as needed. Avoid intravenous administration during labor due to risk of uterine atony.
Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential; use cautiously in patients with history of substance abuse. Combination with other CNS depressants (e.g., alcohol, benzodiazepines) increases sedation risk. Limit use to 2-3 weeks due to lack of efficacy beyond that and risk of dependence. Avoid in patients with porphyria because carisoprodol may be porphyrinogenic.
Monitor liver function tests before and during therapy; hepatotoxicity risk increases with doses >300 mg/day. Do not use in patients with pre-existing hepatic disease. Abrupt discontinuation may precipitate hyperthermia and spasticity rebound. Use with caution in patients with impaired pulmonary function due to potential respiratory muscle weakness.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants while taking this drug.,Take only as prescribed; do not increase dose or frequency. This drug has abuse potential.,Inform your doctor if you have a history of drug or alcohol abuse, seizures, or liver/kidney disease.,Do not use for longer than 2-3 weeks unless directed by your doctor.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Report signs of liver problems: yellow skin/eyes, dark urine, abdominal pain, unusual fatigue.,Do not stop taking suddenly; dose must be tapered to avoid withdrawal symptoms.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how you react.,Avoid alcohol and other CNS depressants while taking this medication.,Use sun protection as photosensitivity may occur.
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARISOPRODOL COMPOUND vs DANTRIUM, answered by our medical review team.
CARISOPRODOL COMPOUND is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.. DANTRIUM is a Skeletal Muscle Relaxant that works by Dantrolene inhibits calcium release from the sarcoplasmic reticulum by binding to the ryanodine receptor (Ry R1), thereby reducing intracellular calcium concentration and decreasing muscle contraction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARISOPRODOL COMPOUND and DANTRIUM depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARISOPRODOL COMPOUND is: 1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.. The standard adult dose of DANTRIUM is: Initially 25 mg orally once daily for 7 days, then 25 mg three times daily for 7 days, then 50 mg three times daily for 7 days, then 100 mg three times daily; maximum 400 mg/day in divided doses. For malignant hyperthermia crisis: IV bolus 1 mg/kg, repeated as needed up to 10 mg/kg cumulative dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARISOPRODOL COMPOUND and DANTRIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARISOPRODOL COMPOUND is classified as Category A/B. Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fe. DANTRIUM is classified as Category C. Dantrolene (Dantrium) is classified as FDA Pregnancy Category C. Animal studies have shown an increased incidence of fetal resorptions and delayed ossification at doses ≥ 30 mg/kg/. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.